Table 1.
Summary of outcomes with tocilizumab in sarcoidosis.
| Primary Manifestationa |
Prednisone Dose | Symptoms | Pulmonary Function Tests (Phenotype and Response) | |
|---|---|---|---|---|
| Patient 1 | Pulmonary | 15 mg-5 mg (66% reduction) | Improved | Restrictive FVC% predicted 49 to 55 Obstructive FEV1/FVC stable FEV1% predicted: 38 to 42 |
| Patient 2 | Lupus Pernio Sinus Disease Pulmonary |
15 mg-5 mg (66% reduction) | Improved | Normal pattern |
| Patient 3 | Pulmonary Arthralgias Abdominal |
15 mg-10 mg (33% reduction) | Improved | Gas Transfer Defect DLCO% predicted: 62 to 80 |
| Patient 4 | Pulmonary Intractable Chest Pain |
20 mg-10 mg (50% reduction) | Improved | Restrictive FVC% predicted: 78 to 84 |
a
Primary manifestation refers to organ involvement that directed steroid sparing therapy.